TRIM-edicine is an early-stage, privately held biotechnology company engaged in the development of novel biopharmaceutical products for the treatment of several important unmet medical needs, including oral healthcare, dermal wounds, ischemia/reperfusion injury, sports medicine and muscular dystrophy. The company is built around a core of protein therapeutic approaches that involve novel proteins with remarkable biological properties. These unique proteins target a variety of cellular pathways that are altered in numerous disease states. R&D efforts at TRIM-edicine focus on providing proof-of-concept support to validate our technology and facilitate partnerships with various established companies in the biomedical field.

TRIM-edicine specializes in the isolation of unique recombinant proteins (left) and engineering these proteins (right) for the application in healthcare therapeutics. We also continue to develop our product pipeline into small molecule therapeutics using a novel high-throughput sceening methodology (bottom).


TRIM-edicine, Inc.
Commercialization Center for Innovative Technology
Suite 126
675 US Highway 1
North Brunswick, NJ 08902
(732)729-6255
info@trim-edicine.com